{"id":81747,"date":"2026-05-13T16:48:11","date_gmt":"2026-05-13T16:48:11","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/81747\/"},"modified":"2026-05-13T16:48:11","modified_gmt":"2026-05-13T16:48:11","slug":"novo-nordisk-highlights-new-wegovy-pill-data-novo-nordisk-nysenvo","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/81747\/","title":{"rendered":"Novo Nordisk Highlights New Wegovy Pill Data &#8211; Novo Nordisk (NYSE:NVO)"},"content":{"rendered":"<p class=\"block core-block\">The company <a target=\"_blank\" href=\"https:\/\/www.novonordisk.com\/content\/nncorp\/global\/en\/news-and-media\/news-and-ir-materials\/news-details.html?id=916548\" rel=\"noreferrer noopener nofollow\">said<\/a> adults treated with oral semaglutide 25 mg achieved clinically meaningful weight loss regardless of whether they experienced rapid early reductions in body weight.<\/p>\n<p>Early Responders Saw Greater Long-Term Weight Loss<\/p>\n<p class=\"block core-block\">According to the new analysis, nearly 29% of participants classified as &#8220;early responders&#8221; \u2014 those who lost at least 10% of body weight by week 16 \u2014 recorded average weight loss of 13.2% at that stage of treatment.<\/p>\n<p class=\"block core-block\">By week 64, those early responders achieved an <a target=\"_blank\" href=\"https:\/\/www.benzinga.com\/general\/biotech\" rel=\"noreferrer noopener nofollow\">average weight loss of 21.6%<\/a>.<\/p>\n<p class=\"block core-block\">Participants who did not meet the early-response benchmark still reported average weight loss of 11.5% by the end of the study.<\/p>\n<p>Wegovy Pill Also Improved Physical Function<\/p>\n<p class=\"block core-block\">A separate OASIS 4 analysis showed nearly eight in 10 participants with poor physical function experienced clinically meaningful improvements in function scores while taking the Wegovy pill, compared with 42.9% in the placebo group.<\/p>\n<p class=\"block core-block\">The scores measured physical capabilities, including stamina and range of motion. Novo Nordisk said participants in this subgroup achieved weight loss comparable to the <a target=\"_blank\" href=\"https:\/\/www.benzinga.com\/general\/biotech\" rel=\"noreferrer noopener nofollow\">broader treatment population<\/a>.<\/p>\n<p>Novo Nordisk Compared Wegovy Pill With Orforglipron<\/p>\n<p class=\"block core-block\">Additional analyses presented at ECO2026 suggested that the Wegovy pill produced greater weight loss and lower discontinuation rates due to gastrointestinal side effects than orforglipron.<\/p>\n<p class=\"block core-block\">In the OPTIC patient preference survey, 84% of respondents favored a treatment profile similar to the Wegovy pill over one resembling orforglipron.<\/p>\n<p class=\"block core-block\">Novo Nordisk added that the latest findings support the primary OASIS 4 trial results, which showed an average weight loss of 17% among adults taking the Wegovy pill versus 2.7% among placebo participants.<\/p>\n<p class=\"block core-block\">NVO Price Action: Novo Nordisk shares were down 0.11% at $46.95 at the time of publication on Wednesday, according to Benzinga Pro. Over the past month, NVO has gained about 26.4% versus a 9.1% rise in the S&amp;P 500 and is down roughly 9% year-to-date compared to the index\u2019s 7.8% gain.<\/p>\n<p class=\"block core-block\">Image via Shutterstock<\/p>\n<p><a class=\"text-sm my-4\" href=\"https:\/\/www.benzinga.com\/apis?utm_source=benzinga.com&amp;utm_campaign=article-bottom\" rel=\"noreferrer nofollow noopener\" target=\"_blank\">Market News and Data brought to you by Benzinga APIs<\/a><\/p>\n<p class=\"copyright\">\u00a9 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.<\/p>\n<p class=\"block core-block\">To add Benzinga News as your preferred source on Google, <a href=\"https:\/\/google.com\/preferences\/source?q=https%3A%2F%2Fwww.benzinga.com\" rel=\"noreferrer nofollow noopener\" target=\"_blank\">click here<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"The company said adults treated with oral semaglutide 25 mg achieved clinically meaningful weight loss regardless of whether&hellip;\n","protected":false},"author":2,"featured_media":81748,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[271],"tags":[2085,2094,2089,2087,2088,2084,272,352,2096,2099],"class_list":{"0":"post-81747","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-novo-nordisk","8":"tag-category-biotech","9":"tag-category-general","10":"tag-category-health-care","11":"tag-category-large-cap","12":"tag-category-news","13":"tag-cms-wordpress","14":"tag-novo-nordisk","15":"tag-pageisbzpro-bz","16":"tag-symbol-nvo","17":"tag-tag-weight-loss"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116568294353513666","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/81747","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=81747"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/81747\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/81748"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=81747"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=81747"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=81747"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}